WEXFORD,
Pa., Jan. 22, 2025 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or
"Coeptis"), a biopharmaceutical company focused on pioneering cell
therapy platforms for cancer, autoimmune, and infectious diseases,
today announced it has regained compliance with Listing Rule
5550(a)(2) (the "Bid Price Rule"), as required by the Nasdaq
Hearings Panel's decision of September 17,
2024.
"We thank the Nasdaq Hearings Panel for approving our request,"
said Coeptis' Chief Executive Officer Dave
Mehalick. "Regaining compliance with Nasdaq's listing
standards is an encouraging start to what we believe will be a
transformative year for Coeptis."
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics, Inc., Coeptis
Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP
Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical
and technology company focused on developing innovative cell
therapy platforms for cancer, autoimmune, and infectious diseases.
Coeptis aims to advance treatment paradigms and improve patient
outcomes through its cutting-edge research and development
efforts.
The Company's therapeutic portfolio is underscored by assets
licensed from Deverra Therapeutics, which include an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. Coeptis is also
developing a universal, multi-antigen CAR technology licensed from
the University of Pittsburgh
(SNAP-CAR), alongside GEAR cell therapy and companion diagnostic
platforms in collaboration with VyGen-Bio and distinguished medical
researchers at the Karolinska
Institute.
Building on its core competencies, Coeptis has recently
established a Technology Division, which focuses on enhancing
operational capabilities through advanced technologies. This
division features AI-powered marketing software and robotic process
automation tools acquired from NexGenAI Solutions Group, designed
to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA,
Coeptis is dedicated to advancing its mission within the regulatory
framework set forth by the FDA, ensuring that all activities align
with the highest standards of compliance and patient care. For more
information on Coeptis, visit https://coeptistx.com
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the inability to recognize the anticipated
benefits of the Deverra licensed assets, which may be affected by,
among other things, competition, the ability of the Company to grow
and manage growth economically and hire and retain key employees;
(3) the risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (4) costs related to ongoing asset
development including the Deverra licensed assets and pursuing the
contemplated asset development paths; (5) changes in applicable
laws or regulations; (6) the possibility that the Company may be
adversely affected by other economic, business, and/or competitive
factors; and (7) the impact of the global COVID-19 pandemic on any
of the foregoing risks and other risks and uncertainties identified
in the Company's filings with the Securities and Exchange
Commission (the "SEC"). The foregoing list of factors is not
exclusive. All forward-looking statements are subject to
significant uncertainties and risks including, but not limited, to
those risks contained or to be contained in reports and other
filings filed by the Company with the SEC. For these reasons, among
others, investors are cautioned not to place undue reliance upon
any forward-looking statements in this press release. Additional
factors are discussed in the Company's filings made or to be made
with the SEC, which are available for review at www.sec.gov. We
undertake no obligation to publicly revise these forward-looking
statements to reflect events or circumstances that arise after the
date hereof unless required by applicable laws, regulations, or
rules.
Contacts
IR@coeptistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-regains-compliance-with-nasdaq-listing-rule-5550a2-302356887.html
SOURCE Coeptis Therapeutics, Inc.
